Return to the home page. top banner right
top banner bottom
Click to search.
members
Login:
Password:
Click to login
Click for Log In Help
Click to Join the Society
 
 
 
 
Click for the Heart Rhythm Foundation
Click for the IBHRE (formerly NASPExAM)
Click for Professional Education
 
 
 
 
 
 
 
 
Click for Health Policy
Click for News & Information
Click for Scientific Sessions
Click for the HRS Calendar
Click for the HeartRhythm Journal
Click for the HRS Store
Click to Find a Specialist
Click for Patient Information
Click for About HRS
Click for Membership
titlelines PASE Clinical Trial
Pacing Mode Choice (Mixed)

Title of Trial
Pacemaker Selection in the Elderly (PASE) study

Date and Citation of Primary Publication(s) or References
Lamas GA, Orav EJ, Stambler BS, et al. Quality of life and clinical outcomes in elderly patients treated with ventricular pacing as compared to with dual chamber pacing. Pacemaker Selection in the Elderly Investigators. N Eng J Med 1998; 338: 1097-1104.

Purpose of the Trial
Evaluate the effects of pacing mode choice in elderly patients with bradycardia.

Study Category
Pacing

Patient Population
Inclusion Criteria
Patients older than 65 years, in sinus rhythm, who required a pacemaker for bradycardia.

Exclusion Criteria
Patients who could not participate in quality of life evaluations, patients with clinically overt congestive heart failure at implantation, patients with permanent atrial fibrillation (no episodes of sinus rhythm for six months), patients with a serious noncardiac illness, and patients with inadequate atrial capture or sensing thresholds.

Study Design
Single blind randomized controlled comparison. Patients were randomized to the VVIR or DDDR pacing mode at enrollment.

Primary Endpoints
Health related quality-of-life (SF-36).

Secondary Endpoints
Death from all causes, first nonfatal stroke or death, first hospitalization for heart failure, development of atrial fibrillation, development of pacemaker syndrome.

Baseline Characteristics
Patient number: 407 patients
Mean Age: 76 years (range: 65-96 years)
Gender: 40% female
Other characteristics:
Indications for permanent pacing: Atrioventricular block: 49%, sinus node dysfunction: 43%, other: 8%. Ventriculoatrial conduction was present in 29% at time of implantation. Other problems included 29% with a history of supraventricular tachycardia (including atrial fibrillation), 27% with a history of heart failure, and baseline cerebrovascular disease in 13%.

Time to Follow-up
Quality of life evaluation at 3, 9, and 18 months.

Results
Quality-of-life improved with both pacing modes compared to baseline. No differences in quality-of-life were noted between the two pacing modes. A 26% crossover rate due to development of pacemaker syndrome was observed. No differences in clinical outcomes were detected between the pacing modes: Death (VVIR: 17% vs. DDDR: 16%, p = 0.95), Stroke, heart failure hospitalization, and death (VVIR: 27% vs. DDDR: 22%; p = 0.18), and development of atrial fibrillation (VVIR: 19% vs. DDDR: 17%; p = 0.80). In the prespecified subgroup analysis, sinus node dysfunction patients were evaluated separately. In this subgroup dual chamber pacing was associated with mild improvements in the role-emotional and social function subscales. In addition, dual chamber pacing was also associated with borderline but non-significant improvement in clinical endpoints: Death (VVIR: 20% vs. DDDR: 12%, p = 0.09), the combined endpoint of stroke, heart failure hospitalization, and death (VVIR: 31% vs. DDDR: 20%; p = 0.07), and development of atrial fibrillation (VVIR: 28% vs. DDDR: 19%; p = 0.06). For patients with atrioventricular block no differences in the clinical endpoints or quality-of-life could be detected between the VVIR and DDDR pacing modes.

Overall population

Endpoint VVIR
(n=204)
DDDR
(n=203)
P
All cause mortality 17% 16% 0.95
Stroke or death 19% 17% 0.75
Stroke or death or hospitalization for heart failure 27% 22% 0.18
Atrial fibrillation 19% 17% 0.80


Sinus node dysfunction

Endpoint VVIR
 (n=85) 
DDDR
 (n=90)
 
P
All cause mortality 20% 12% 0.09
Stroke or death 22% 13% 0.11
Stroke or death or hospitalization for heart failure 31% 20% 0.07
Atrial fibrillation 28% 19% 0.06


Atrioventricular block

Endpoint VVIR
(n=204)
DDDR
(n=203)
P
All cause mortality 15% 17% 0.41
Stroke or death 18% 18% 0.68
Stroke or death or hospitalization for heart failure 26% 21% 0.49
Atrial fibrillation 11% 16% 0.26


Sponsor
Intermedics

Trial Status:  Completed

Click to Print Page.Click to Email Page. Click to Contact Us.Click for the Site Map.
© Heart Rhythm Society      1400 K St NW ste 500      Washington DC 20005      tel 202.464.3400      fax 202.464.3401